Back to results
US 2017/0319682 A1Published application
Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
AssigneeNovavax, Inc.
InventorsGale SMITH, Yingyun WU, Michael MASSARE, Ye LIU
Life of this patent
Estimating the term…
Abstract
The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
Claims17
1-55. (canceled)
A kit for immunizing a human subject against an RSV infection comprising
- a first container comprising lyophilized RSV F protein wherein the RSV F protein comprises at least one modification or mutation, and
- a second container comprising pharmaceutically acceptable carrier, diluent, or excipient.
57-76. (canceled)
Dependencies are inferred from the claim text.